Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

6533b85afe1ef96bd12b95d2

RESEARCH PRODUCT

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

Federico Longo Muñoz Guillem Argilés Martínez Josep Tabernero Andrés Cervantes Cristina Grávalos Carles Pericay S. Gil Calle Hirokazu Mizuguchi Alfredo Carrato María Luisa Limón Rocio García Carbonero Universitat Autònoma De Barcelona

subject

Male 0301 basic medicine Oncology Cancer Research Pyrrolidines Colorectal cancer Trifluridine Helsinki declaration law.invention Trifluridine chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Medicine Aged 80 and over Metastatic colorectal cancer Palliative Care Hazard ratio General Medicine Middle Aged Prognosis TAS-102 Survival Rate Drug Combinations Oncology 030220 oncology & carcinogenesis Drug Therapy Combination Female Colorectal Neoplasms Fluoropyrimidine Research Article medicine.drug Adult medicine.medical_specialty animal structures Subgroup analysis Placebo Antiviral Agents 03 medical and health sciences Double-Blind Method Internal medicine Humans Tipiracil hydrochloride Uracil Aged Neoplasm Staging Tipiracil business.industry medicine.disease Surgery 030104 developmental biology chemistry Spain business Thymine Follow-Up Studies

description

[Purpose] TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P < 0.001]. The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup.

year	journal	country	edition	language
2016-07-01	Clinical and Translational Oncology

10.1007/s12094-016-1528-7 http://hdl.handle.net/10261/198649